Holen Sie sich die Stockscreener-App
44.64
3.31%
1.43
Handel nachbörslich:
44.36
-0.28
-0.63%
Schlusskurs vom Vortag:
$43.21
Offen:
$43.49
24-Stunden-Volumen:
132.53K
Relative Volume:
1.09
Marktkapitalisierung:
$493.52M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+14.26%
1M Leistung:
+68.71%
6M Leistung:
+123.20%
1J Leistung:
+0.00%
1-Tages-Spanne:
$42.89
$46.35
1-Wochen-Bereich:
$37.33
$46.35
52-Wochen-Spanne:
$11.17
$46.35
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Firmenname
Palvella Therapeutics Inc
Sektor
Branche
Telefon
(484) 253-1461
Adresse
125 STRAFFORD AVE, WAYNE
Vergleichen Sie PVLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
44.64 | 477.72M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Eingeleitet | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-04-09 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-26 | Eingeleitet | Stifel | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-05 | Eingeleitet | TD Cowen | Buy |
| 2024-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-19 | Eingeleitet | Jefferies | Buy |
| 2018-01-16 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-30 | Eingeleitet | Rodman & Renshaw | Buy |
| 2016-08-05 | Fortgesetzt | ROTH Capital | Buy |
| 2015-08-12 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-07-27 | Eingeleitet | Oppenheimer | Outperform |
| 2015-07-22 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten
Will Palvella Therapeutics Inc. stock recover after recent dropMarket Volume Report & Safe Swing Trade Setups - Newser
Palvella Therapeutics Inc. stock volume spike explainedJuly 2025 Outlook & Safe Capital Preservation Plans - Newser
Palvella Therapeutics Inc. stock momentum explainedJuly 2025 Outlook & Weekly High Return Stock Opportunities - Newser
What indicators show strength in Palvella Therapeutics Inc.Weekly Trend Recap & Community Trade Idea Sharing - Newser
Is Palvella Therapeutics Inc. forming a reversal patternSwing Candidate List with Trade Cues - Newser
Is Palvella Therapeutics Inc. stock entering bullish territorySecure Buy Strategy Based on Risk Parameters - Newser
How hedge fund analytics apply to Palvella Therapeutics Inc. stockFree Stock Selection With High Accuracy - Newser
Exit strategy if you’re trapped in Palvella Therapeutics Inc.Smart Money Strategy for Growth Stocks - Newser
Palvella Therapeutics CEO to Speak at Canaccord Genuity Growth Conference - MSN
Risk vs reward if holding onto Palvella Therapeutics Inc.Portfolio Risk Distribution Analysis Tool - Newser
Palvella Therapeutics (PVLA) to Release Earnings on Thursday - Defense World
Detecting price anomalies in Palvella Therapeutics Inc. with AIFree Daily Chart Pattern Stock Forecast - Newser
What institutional flow reveals about Palvella Therapeutics Inc.Weekly Growth Portfolio Performance Summary - Newser
Palvella Therapeutics to Report Q2 Financials and Corporate Update on August 14 - MSN
Will Palvella Therapeutics Inc. price bounce be sustainableInvestment Life Cycle Planning Summary - Newser
How Palvella Therapeutics Inc. stock performs during market volatilityAsset Allocation Summary With Future Outlook - Newser
Will Palvella Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsBreakout Monitoring with Momentum Analysis - Newser
Palvella Therapeutics Inc. stock trend forecastSwing Gain Strategy with Entry Forecast - Newser
Key External Factors That Drive Palvella Therapeutics Inc. Stock Price MovementsFree Daily Chart Pattern Stock Forecast - Newser
Does Palvella Therapeutics Inc. fit your quant trading modelStock Market Trend and Pattern Analysis - Newser
Real time scanner hits for Palvella Therapeutics Inc. explainedProfitable Trading Blueprint with Entry Zones - Newser
Palvella Therapeutics to report Q2 2025 financial results on Aug 14. - AInvest
Palvella Therapeutics Q2 2025 Earnings Call Scheduled for August 14 | PVLA Stock News - Stock Titan
Analysts Set Expectations for PVLA Q2 Earnings - Defense World
How to read the order book for Palvella Therapeutics Inc.AI Trade Signal Forecast with Chart Logic - Newser
What makes Palvella Therapeutics Inc. stock price move sharplyHigh Yield Signals with Entry Timing - Newser
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Palvella Therapeutics (NASDAQ:PVLA) Rating Increased to Strong-Buy at Lifesci Capital - Defense World
Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
Raymond James Initiates Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $54 - 富途牛牛
Raymond James initiates Palvella Therapeutics stock with Outperform rating By Investing.com - Investing.com Canada
Lifesci Capital Initiates Coverage on Palvella Therapeutics (NASDAQ:PVLA) - Defense World
Lifesci Capital Upgrades Palvella Therapeutics (NASDAQ:PVLA) to “Strong-Buy” - Defense World
Palvella Therapeutics CEO to Share Rare Disease Pipeline Updates at Major Growth Conference - Stock Titan
Finanzdaten der Palvella Therapeutics Inc-Aktie (PVLA)
Es liegen keine Finanzdaten für Palvella Therapeutics Inc (PVLA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):